C. Charles, P. Clements, and D. E. Furst, Seminar Systemic sclerosis : hypothesisdriven treatment strategies, 2006.

M. Nikpour, W. M. Stevens, A. L. Herrick, and S. M. Proudman, Epidemiology of systemic sclerosis, Best Practice & Research Clinical Rheumatology, vol.24, issue.6, pp.857-869, 2010.
DOI : 10.1016/j.berh.2010.10.007

V. , L. Guern, A. Mahr, L. Mouthon, D. Jeanneret et al., Prevalence of systemic sclerosis in a French multi-ethnic county, Rheumatology, vol.43, issue.9, pp.1129-1137, 2004.

M. Cutolo, A. Sulli, C. Pizzorni, S. Paolino, and V. Smith, Systemic sclerosis: Markers and targeted treatments, Acta Reumatol. Port, vol.2016, issue.1, pp.18-25, 2016.

M. Elhai, C. Meune, J. Avouac, A. Kahan, and Y. Allanore, Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies, Rheumatology, vol.29, issue.1, pp.1462-0332, 2012.
DOI : 10.1111/j.1445-5994.1999.tb01587.x

M. Rubio-rivas, C. Royo, C. P. Simeón, X. Corbella, and V. Fonollosa, Mortality and survival in systemic sclerosis: Systematic review and meta-analysis, Seminars in Arthritis and Rheumatism, vol.44, issue.2, pp.208-219, 2014.
DOI : 10.1016/j.semarthrit.2014.05.010

B. Admou, L. Essaadouni, S. Amal, N. Arji, L. Chabaa et al., Autoanticorps au cours de la sclérodermie systémique: intérêt clinique et approche diagnostique, pp.273-281

A. T. Masi, Preliminary criteria for the classification of systemic sclerosis (scleroderma), Arthritis & Rheumatism, vol.52, issue.5, 1980.
DOI : 10.1001/archderm.1943.01500210084005

E. C. Leroy and T. A. Medsger, Criteria for the classification of early systemic sclerosis, J. Rheumatol, vol.28, issue.7, pp.1573-1579, 2001.

I. Marie, J. Gehanno, M. Bubenheim, A. Duval-modeste, P. Joly et al., Prospective study to evaluate the association between systemic sclerosis and occupational exposure and review of the literature, Autoimmunity Reviews, vol.13, issue.2, pp.151-156, 2014.
DOI : 10.1016/j.autrev.2013.10.002

C. Feghali-bostwick, T. A. Medsger, and T. M. Wright, Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies, Arthritis & Rheumatism, vol.22, issue.7, pp.1956-1963, 2003.
DOI : 10.1111/j.0954-6820.1982.tb01929.x

P. Chairta, P. Nicolaou, and K. Christodoulou, Genomic and genetic studies of systemic sclerosis: A systematic review, Human Immunology, vol.78, issue.2, pp.153-165, 2017.
DOI : 10.1016/j.humimm.2016.10.017

G. Witte, P. Riemekasten, R. Airo, C. Scorza, N. Lunardi et al., Identification of CSK as a systemic sclerosis genetic risk factor through Genome Wide Association Study follow-up, Hum. Mol. Genet, vol.21, issue.12, pp.2825-2860, 2012.

P. Dieudé, M. Guedj, J. Wipff, B. Ruiz, E. Hachulla et al., on disease susceptibility and related pulmonary fibrosis, Arthritis & Rheumatism, vol.71, issue.Pt 2, pp.2472-2479, 2009.
DOI : 10.4049/jimmunol.182.1.34

B. Rueda, P. Gourh, J. Broen, S. K. Agarwal, C. Simeon et al., BANK1 functional variants are associated with susceptibility to diffuse systemic sclerosis in Caucasians, Annals of the Rheumatic Diseases, vol.69, issue.4, pp.700-705, 2010.
DOI : 10.1136/ard.2009.118174

C. Lok, L. Mouthon, M. Ségard, M. Richard, and L. Guillevin, Les ulc??res digitaux de la scl??rodermie syst??mique, Annales de Dermatologie et de V??n??r??ologie, vol.138, issue.11, pp.762-770, 2011.
DOI : 10.1016/j.annder.2011.06.011

M. Manetti, S. Guiducci, L. Ibba-manneschi, and M. Matucci-cerinic, Mechanisms in the loss of capillaries in systemic sclerosis: angiogenesis versus vasculogenesis, Journal of Cellular and Molecular Medicine, vol.120, issue.6a, pp.1241-1254, 2010.
DOI : 10.1161/CIRCULATIONAHA.109.855114

H. M. Farouk, S. H. Hamza, S. A. Bakry, S. S. Youssef, I. M. Aly et al., Dysregulation of angiogenic homeostasis in systemic sclerosis, International Journal of Rheumatic Diseases, vol.71, issue.9, pp.448-454, 2013.
DOI : 10.1136/annrheumdis-2011-200657

J. Choi, D. Min, M. Cho, S. Min, S. Kim et al., Elevated vascular endothelial growth factor in systemic sclerosis, J. Rheumatol, vol.30, issue.7, pp.1529-1562, 2003.

O. Distler, J. H. Distler, A. Scheid, T. Acker, A. Hirth et al., Uncontrolled Expression of Vascular Endothelial Growth Factor and Its Receptors Leads to Insufficient Skin Angiogenesis in Patients With Systemic Sclerosis, Circulation Research, vol.95, issue.1, pp.109-116, 2004.
DOI : 10.1161/01.RES.0000134644.89917.96

Y. Qiu, C. Hoareau-aveilla, S. Oltean, S. J. Harper, and D. O. Bates, The anti-angiogenic isoforms of VEGF in health and disease, Biochemical Society Transactions, vol.37, issue.6, pp.1207-1213, 2009.
DOI : 10.1042/BST0371207

M. Manetti, S. Guiducci, E. Romano, S. Bellando-randone, G. Lepri et al., b splice variant are associated with the severity of nailfold capillary loss in systemic sclerosis, Annals of the Rheumatic Diseases, vol.27, issue.8, pp.1425-1427, 2013.
DOI : 10.1136/annrheumdis-2011-200837

M. Manetti, S. Guiducci, E. Romano, C. Ceccarelli, S. Bellando-randone et al., Overexpression of VEGF165b, an Inhibitory Splice Variant of Vascular Endothelial Growth Factor, Leads to Insufficient Angiogenesis in Patients With Systemic Sclerosis, Circulation Research, vol.109, issue.3, pp.14-26, 2011.
DOI : 10.1161/CIRCRESAHA.111.242057

M. Matucci-cerinic, B. Kahaleh, and F. M. Wigley, Review: Evidence That Systemic Sclerosis Is a Vascular Disease, Arthritis & Rheumatism, vol.170, issue.Suppl 3, pp.1953-1962, 2013.
DOI : 10.1164/rccm.200308-1151OC

T. Asahara and J. M. Isner, Endothelial Progenitor Cells for Vascular Regeneration, Journal of Hematotherapy & Stem Cell Research, vol.11, issue.2, pp.171-178, 2002.
DOI : 10.1089/152581602753658385

URL : http://www.rbm.hiroshima-u.ac.jp/rcm-coe/file/fourth/pdf/Asahara.pdf

S. Zhu, S. Evans, B. Yan, T. J. Povsic, V. Tapson et al., Transcriptional Regulation of Bim by FOXO3a and Akt Mediates Scleroderma Serum???Induced Apoptosis in Endothelial Progenitor Cells, Circulation, vol.118, issue.21, pp.2156-2165, 2008.
DOI : 10.1161/CIRCULATIONAHA.108.787200

A. Bordron, M. Dueymes, Y. Levy, C. Jamin, J. P. Leroy et al., The binding of some human antiendothelial cell antibodies induces endothelial cell apoptosis., Journal of Clinical Investigation, vol.101, issue.10, pp.2029-2064, 1998.
DOI : 10.1172/JCI2261

N. Del-papa, N. Quirici, C. Scavullo, U. Gianelli, L. Corti et al., Antiendothelial Cell Antibodies Induce Apoptosis of Bone Marrow Endothelial Progenitors in Systemic Sclerosis, The Journal of Rheumatology, vol.37, issue.10, pp.2053-2063, 2010.
DOI : 10.3899/jrheum.091346

T. Nevskaya, S. Bykovskaia, E. Lyssuk, I. Shakhov, M. Zaprjagaeva et al., Circulating endothelial progenitor cells in systemic sclerosis: relation to impaired angiogenesis and cardiovascular manifestations, Clin. Exp. Rheumatol, vol.26, issue.3, pp.421-429, 2008.

J. H. Le and K. I. Cho, Association between endothelial function and microvascular changes in patients with secondary Raynaud???s phenomenon, Clinical Rheumatology, vol.45, issue.11, 2014.
DOI : 10.1093/rheumatology/kel310

M. B. Kahaleh, I. Osborn, and E. C. Leroy, Increased Factor VIII/von Willebrand Factor Antigen and von Willebrand Factor Activity in Scleroderma and in Raynaud's Phenomenon, Annals of Internal Medicine, vol.94, issue.4_Part_1, pp.482-484, 1981.
DOI : 10.7326/0003-4819-94-4-482

S. Ohdama, S. Takano, S. Miyake, T. Kubota, K. Sato et al., Plasma Thrombomodulin as a Marker of Vascular Injuries in Collagen Vascular Diseases, American Journal of Clinical Pathology, vol.101, issue.1, pp.109-113, 1994.
DOI : 10.1093/ajcp/101.1.109

E. Cozzani, S. Javor, E. Laborai, M. Drosera, and A. Parodi, Endothelin-1 Levels in Scleroderma Patients: A Pilot Study, ISRN Dermatology, vol.183, issue.1, p.125632, 2013.
DOI : 10.1111/j.1346-8138.2011.01299.x

M. B. Kahaleh, Endothelin, an endothelial-dependent vasoconstrictor in scleroderma. Enhanced production and profibrotic action, Arthritis & Rheumatism, vol.159, issue.8, pp.978-83, 1991.
DOI : 10.1111/j.1349-7006.1989.tb02310.x

A. Sulli, S. Soldano, C. Pizzorni, P. Montagna, M. E. Secchi et al., Raynaud's Phenomenon and Plasma Endothelin: Correlations with Capillaroscopic Patterns in Systemic Sclerosis, The Journal of Rheumatology, vol.36, issue.6, pp.1235-1239, 2009.
DOI : 10.3899/jrheum.081030

T. F. Lüscher and M. Barton, Endothelins and Endothelin Receptor Antagonists : Therapeutic Considerations for a Novel Class of Cardiovascular Drugs, Circulation, vol.102, issue.19, pp.2434-2440, 2000.
DOI : 10.1161/01.CIR.102.19.2434

A. Joglekar, F. S. Tsai, D. A. Mccloskey, J. E. Wilson, J. R. Seibold et al., Bosentan in pulmonary arterial hypertension secondary to scleroderma, J. Rheumatol, vol.33, issue.1, pp.61-68, 2006.

T. Tingey, J. Shu, J. Smuczek, and J. Pope, Meta-Analysis of Healing and Prevention of Digital Ulcers in Systemic Sclerosis, Arthritis Care & Research, vol.7, issue.Suppl, pp.1460-1471, 2013.
DOI : 10.1093/rheumatology/ken001

F. M. Meier, K. W. Frommer, R. Dinser, U. Walker, L. Czirjak et al., Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database, Annals of the Rheumatic Diseases, vol.71, issue.8, pp.1355-1360, 2012.
DOI : 10.1136/annrheumdis-2011-200742

V. Steen, C. P. Denton, J. E. Pope, and M. Matucci-cerinic, Digital ulcers: overt vascular disease in systemic sclerosis, Rheumatology, vol.65, issue.suppl_3, pp.19-24, 2006.
DOI : 10.1056/NEJM199104183241618

URL : https://academic.oup.com/rheumatology/article-pdf/48/suppl_3/iii19/18096586/kep105.pdf

M. Baron, L. Chung, G. Gyger, L. Hummers, D. Khanna et al., Consensus opinion of a North American Working Group regarding the classification of digital ulcers in systemic sclerosis, Clinical Rheumatology, vol.49, issue.2, pp.207-214, 2014.
DOI : 10.1093/rheumatology/keq291

C. P. Denton, T. Krieg, L. Guillevin, B. Schwierin, D. Rosenberg et al., Demographic, clinical and antibody characteristics of patients with digital ulcers in systemic sclerosis: data from the DUO Registry, Annals of the Rheumatic Diseases, vol.71, issue.5, pp.718-721, 2012.
DOI : 10.1136/annrheumdis-2011-200631

S. Khimdas, S. Harding, A. Bonner, B. Zummer, M. Baron et al., Associations with digital ulcers in a large cohort of systemic sclerosis: Results from the Canadian Scleroderma Research Group registry, Arthritis Care & Research, vol.60, issue.Suppl 29, pp.142-149, 2011.
DOI : 10.1002/art.24333

I. Meurer, G. Melchers, D. Riemekasten, and . Centers, Comparison of patients with and without digital ulcers in systemic sclerosis: detection of possible risk factors, Br. J. Dermatol, vol.160, issue.4, pp.835-878, 2009.

K. P. Tiev, E. Diot, P. Clerson, F. Dupuis-siméon, E. Hachulla et al., Clinical Features of Scleroderma Patients With or Without Prior or Current Ischemic Digital Ulcers: Post-Hoc Analysis of a Nationwide Multicenter Cohort (ItinerAIR-Sclerodermie), The Journal of Rheumatology, vol.36, issue.7, pp.1470-1476, 2009.
DOI : 10.3899/jrheum.081044

M. Cutolo, A. L. Herrick, O. Distler, M. O. Becker, E. Beltran et al., Nailfold Videocapillaroscopic Features and Other Clinical Risk Factors for Digital Ulcers in Systemic Sclerosis: A Multicenter, Prospective Cohort Study, Arthritis & Rheumatology, vol.25, issue.Suppl 91, pp.2527-2566, 2016.
DOI : 10.1002/sim.2680

L. Guillevin, E. Hunsche, C. P. Denton, T. Krieg, B. Schwierin et al., Functional impairment of systemic scleroderma patients with digital ulcerations: results from the DUO Registry Clin

S. I. Nihtyanova, G. M. Brough, C. M. Black, and C. P. Denton, Clinical burden of digital vasculopathy in limited and diffuse cutaneous systemic sclerosis, Annals of the Rheumatic Diseases, vol.67, issue.1, pp.120-123, 2008.
DOI : 10.1136/ard.2007.072686

P. Cozzi, M. Airò, U. Cutolo, M. Mueller-ladner, and . Matucci-cerinic, Digital ulcers predict a worse disease course in patients with systemic sclerosis, Ann. Rheum. Dis, 2014.

O. Alegre-sancho, G. Kowal-bielecka, M. Rey, Y. Matucci-cerinic, and . Allanore, Mapping and predicting mortality from systemic sclerosis, Ann. Rheum. Dis, pp.2017-211448, 2017.

Y. Allanore, C. P. Denton, T. Krieg, P. Cornelisse, D. Rosenberg et al., Clinical characteristics and predictors of gangrene in patients with systemic sclerosis and digital ulcers in the Digital Ulcer Outcome Registry: a prospective, observational cohort, Annals of the Rheumatic Diseases, vol.71, issue.(Suppl 76), pp.1736-1776, 2016.
DOI : 10.1136/annrheumdis-2011-200631

C. Tolosa-vilella, M. L. Morera-morales, C. P. Simeón-aznar, B. Marí-alfonso, D. Colunga-arguelles et al., Digital ulcers and cutaneous subsets of systemic sclerosis: Clinical, immunological, nailfold capillaroscopy, and survival differences in the Spanish RESCLE Registry, Fonollosa-Pla, and RESCLE Investigators, pp.200-208, 2016.
DOI : 10.1016/j.semarthrit.2016.04.007

. Matucci-cerinic, Digital ulcers in scleroderma: staging, characteristics and sub-setting through observation of 1614 digital lesions

H. Ennis, M. E. Anderson, J. Wilkinson, and A. L. Herrick, Calcium channel blockers for primary Raynaud's phenomenon, Cochrane Database of Systematic Reviews, p.2069, 2014.

A. E. Thompson and J. E. Pope, Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis, Rheumatology, vol.15, issue.5, pp.145-150, 2005.
DOI : 10.1097/00005344-199005000-00023

J. Hughes, J. Lockhart, and A. Joyce, Do calcium antagonists contribute to gastro-oesophageal reflux disease and concomitant noncardiac chest pain?, British Journal of Clinical Pharmacology, vol.19, issue.1, pp.83-92, 2007.
DOI : 10.1177/00912700122010654

URL : http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2125.2007.02851.x/pdf

M. Rademaker, E. D. Cooke, N. E. Almond, J. A. Beacham, R. E. Smith et al., Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study., BMJ, vol.298, issue.6673, pp.561-565, 1989.
DOI : 10.1136/bmj.298.6673.561

É. Hachulla, D. Launay, and P. Hatron, L???iloprost dans le traitement de la scl??rodermie syst??mique, La Presse M??dicale, vol.37, issue.5, pp.831-839, 2008.
DOI : 10.1016/j.lpm.2007.06.016

F. M. Wigley, R. A. Wise, J. R. Seibold, D. A. Mccloskey, G. Kujala et al., Intravenous Iloprost Infusion in Patients with Raynaud Phenomenon Secondary to Systemic Sclerosis: A Multicenter, Placebo-controlled, Double-Blind Study, Annals of Internal Medicine, vol.120, issue.3, pp.199-206, 1994.
DOI : 10.7326/0003-4819-120-3-199402010-00004

D. B. Badesch, V. F. Tapson, M. D. Mcgoon, B. H. Brundage, L. J. Rubin et al., Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease, Annals of Internal Medicine, vol.132, issue.6, pp.425-459, 2000.
DOI : 10.7326/0003-4819-132-6-200003210-00002

N. J. Mchugh, M. Csuka, H. Watson, G. Belcher, A. Amadi et al., Infusion of iloprost, a prostacyclin analogue, for treatment of Raynaud's phenomenon in systemic sclerosis., Annals of the Rheumatic Diseases, vol.47, issue.1, pp.43-50, 1988.
DOI : 10.1136/ard.47.1.43

F. M. Wigley, J. R. Seibold, R. A. Wise, D. A. Mccloskey, and W. P. Dole, Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis, J. Rheumatol, vol.19, issue.9, pp.1407-1421, 1992.

H. I. Torley, R. Madhok, H. A. Capell, R. M. Brouwer, P. J. Maddison et al., A double blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue diseases., Annals of the Rheumatic Diseases, vol.50, issue.11, pp.800-804, 1991.
DOI : 10.1136/ard.50.11.800

R. Scorza, M. Caronni, B. Mascagni, V. Berruti, S. Bazzi et al., Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study, Clin Exp Rheumatol, vol.19, pp.503-511, 2001.

P. Caramaschi, D. Biasi, S. Canestrini, N. Martinelli, L. Perbellini et al., Evaluation of finger skin temperature in scleroderma patients cyclically treated with iloprost, Joint Bone Spine, vol.73, issue.1, pp.57-61, 2006.
DOI : 10.1016/j.jbspin.2005.04.006

D. Biasi, A. Carletto, P. Caramaschi, S. Zeminian, M. L. Pacor et al., Iloprost as cyclic five-day infusions in the treatment of scleroderma. An open pilot study in 20 patients treated for one year, Rev. Rhum. Engl. Ed, vol.65, issue.12, pp.745-50, 1998.

L. Bettoni, A. Geri, P. Airò, E. Danieli, I. Cavazzana et al., Systemic Sclerosis Therapy with Iloprost: A Prospective Observational Study of 30 Patients Treated for a Median of 3 Years, Clinical Rheumatology, vol.21, issue.3, pp.244-50, 2002.
DOI : 10.1007/PL00011223

P. Airò, M. Rossi, M. Scarsi, E. Danieli, A. Grottolo et al., Diseasemodifying effects of long-term cyclic iloprost therapy in systemic sclerosis. A retrospective analysis and comparison with a control group, Clin. Exp. Rheumatol, vol.25, issue.5, pp.722-729

M. Scarsi, M. Rossi, E. Danieli, A. Frigè, A. Grottolo et al., [Longterm effects of cyclic therapy with iloprost in systemic sclerosis], Reumatismo, vol.60, issue.2, pp.114-123

P. Caramaschi, N. Martinelli, A. Volpe, S. Pieropan, I. Tinazzi et al., A score of risk factors associated with ischemic digital ulcers in patients affected by systemic sclerosis treated with iloprost, Clinical Rheumatology, vol.42, issue.Suppl 29, pp.807-813, 2009.
DOI : 10.1177/1358836X9800300105

P. Caramaschi, A. Gassa, D. Prati, G. Barausse, I. Tinazzi et al., Severe vascular complications in patients affected by systemic sclerosis cyclically treated with iloprost, Rheumatology International, vol.66, issue.suppl 29, pp.1933-1938, 2012.
DOI : 10.1136/ard.2006.066068

M. Colaci, F. Lumetti, D. Giuggioli, S. Guiducci, S. Ballando-randone et al., AB0623???Treatment of Scleroderma-Related Digital Ulcers with Iloprost: A Cohort Study, Annals of the Rheumatic Diseases, vol.75, issue.Suppl 2, pp.1117-1117, 2016.
DOI : 10.1136/annrheumdis-2016-eular.2228

R. Foti, E. Visalli, G. Amato, A. Benenati, G. Converso et al., Long-term clinical stabilization of scleroderma patients treated with a chronic and intensive IV iloprost regimen, Rheumatology International, vol.120, issue.2, pp.245-249, 2017.
DOI : 10.7326/0003-4819-120-3-199402010-00004

F. Catros, Perfusions intraveineuses d'Iloprost : profil des patients et tolérance, 2013.

C. Caballo, G. Escolar, M. Diaz-ricart, I. Lopez-vílchez, M. Lozano et al., Impact of experimental haemodilution on platelet function, thrombin generation and clot firmness: effects of different coagulation factor concentrates, Blood Transfus, vol.11, issue.3, pp.391-400, 2013.

S. Jin, G. Yu, R. Hou, B. Shen, and H. Jiang, Effect of Hemodilution In Vitro with Hydroxyethyl Starch on Hemostasis, Medical Science Monitor, vol.23, pp.2189-2197, 2017.
DOI : 10.12659/MSM.901588

L. L. Hansen, P. Danisevskis, H. R. Arntz, G. Hövener, and M. Wiederholt, A randomised prospective study on treatment of central retinal vein occlusion by isovolaemic haemodilution and photocoagulation., British Journal of Ophthalmology, vol.69, issue.2, pp.108-124, 1985.
DOI : 10.1136/bjo.69.2.108

T. S. Chang and M. B. Jensen, Haemodilution for acute ischaemic stroke, Cochrane database Syst. Rev, vol.16, issue.23, p.103, 2014.
DOI : 10.1161/01.STR.16.5.765

URL : http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD000103.pub2/pdf

D. Chappell, D. Bruegger, J. Potzel, M. Jacob, F. Brettner et al., Hypervolemia increases release of atrial natriuretic peptide and shedding of the endothelial glycocalyx, Critical Care, vol.105, issue.5, p.538, 2014.
DOI : 10.1007/s00395-010-0118-z

R. Fries, K. Shariat, H. Wilmowsky, and M. Böhm, Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy, Circulation, vol.112, issue.19, pp.2980-2985, 2005.

E. Caglayan, M. Huntgeburth, T. Karasch, J. Weihrauch, N. Hunzelmann et al., Phosphodiesterase Type 5 Inhibition Is a Novel Therapeutic Option in Raynaud Disease, Archives of Internal Medicine, vol.166, issue.2, p.231, 2006.
DOI : 10.1001/archinte.166.2.231

G. Carlino, Treatment of Raynaud's phenomenon with tadalafil, a phosphodiesterase-5 inhibitor [abstract], Ann Rheum Dis, vol.64258, issue.64, p.258, 2005.

E. Schiopu, V. M. Hsu, A. J. Impens, J. A. Rothman, D. A. Mccloskey et al., Randomized Placebo-Controlled Crossover Trial of Tadalafil in Raynaud's Phenomenon Secondary to Systemic Sclerosis, The Journal of Rheumatology, vol.36, issue.10, pp.2264-2268, 2009.
DOI : 10.3899/jrheum.090270

P. D. Shenoy, S. Kumar, L. K. Jha, S. K. Choudhary, U. Singh et al., Efficacy of tadalafil in secondary Raynaud???s phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial, Rheumatology, vol.60, issue.12, pp.2420-2428, 2010.
DOI : 10.1002/art.24333

C. S. Brueckner, M. O. Becker, T. Kroencke, D. Huscher, H. U. Scherer et al., Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study, Annals of the Rheumatic Diseases, vol.69, issue.8, pp.1475-1483, 2010.
DOI : 10.1136/ard.2009.116475

C. P. Denton, M. Hughes, N. Gak, J. Vila, M. H. Buch et al., BSR and BHPR guideline for the treatment of systemic sclerosis, Rheumatology, vol.32, issue.6, pp.1906-1916, 2016.
DOI : 10.1001/jama.2014.6368

L. Uppal, K. Dhaliwal, and P. E. Butler, A prospective study of the use of botulinum toxin injections in the treatment of Raynaud???s syndrome associated with scleroderma, Journal of Hand Surgery (European Volume), vol.281, issue.8, pp.876-880, 2014.
DOI : 10.1097/01.prs.0000244860.00674.57

A. Fregene, D. Ditmars, and A. Siddiqui, Botulinum Toxin Type A: A Treatment Option for Digital Ischemia in Patients With Raynaud's Phenomenon, The Journal of Hand Surgery, vol.34, issue.3, pp.446-52, 2009.
DOI : 10.1016/j.jhsa.2008.11.026

M. W. Neumeister, C. B. Chambers, M. S. Herron, K. Webb, J. Wietfeldt et al., Botox Therapy for Ischemic Digits, Plastic and Reconstructive Surgery, vol.124, issue.1, pp.191-201, 2009.
DOI : 10.1097/PRS.0b013e3181a80576

URL : https://doi.org/10.1016/j.jvs.2009.12.053

J. Serri, R. Legré, V. Veit, C. Guardia, and A. Gay, Int??r??t de la toxine botulinique de type A dans le traitement des syndromes de Raynaud s??v??res secondaires ?? la scl??rodermie syst??mique, Annales de Chirurgie Plastique Esth??tique, vol.58, issue.6, pp.658-662, 2013.
DOI : 10.1016/j.anplas.2011.11.001

S. Motegi, K. Yamada, S. Toki, A. Uchiyama, Y. Kubota et al., Beneficial effect of botulinum toxin A on Raynaud's phenomenon in Japanese patients with systemic sclerosis: A prospective, case series study, The Journal of Dermatology, vol.149, issue.1, pp.56-62, 2016.
DOI : 10.1016/j.pain.2010.02.024

P. Guillaume-jugnot, A. Daumas, J. Magalon, E. Jouve, P. Nguyen et al., Autologous adipose-derived stromal vascular fraction in patients with systemic sclerosis: 12-month follow-up, Rheumatology, vol.31, issue.2, pp.301-306, 2016.
DOI : 10.1002/art.10486

URL : https://hal.archives-ouvertes.fr/hal-01452751

F. Benyamine, G. Dignat-george, F. Magalon, B. Sabatier, and . Granel, Long-term follow-up after autologous adipose-derived stromal vascular fraction injection into fingers in systemic sclerosis patients, Curr. Res. Transl. Med, vol.65, issue.1, pp.40-43, 2017.

G. Chiou, C. Crowe, P. Suarez, L. Chung, C. Curtin et al., Digital Sympathectomy in Patients With Scleroderma, Annals of Plastic Surgery, vol.75, issue.6, pp.637-643, 2015.
DOI : 10.1097/SAP.0000000000000614

K. Murata, S. Omokawa, Y. Kobata, Y. Tanaka, H. Yajima et al., Long-term follow-up of periarterial sympathectomy for chronic digital ischaemia, Journal of Hand Surgery (European Volume), vol.3, issue.8, pp.788-93, 2012.
DOI : 10.1097/00000658-198106000-00004

C. S. Pace and W. H. Merritt, Extended Periarterial Sympathectomy: Evaluation of Long-Term Outcomes, HAND, vol.1, p.155894471771511, 2017.
DOI : 10.1097/00000658-198106000-00004

C. Gaitonde and . Black, Digital ulcers in systemic sclerosis: Prevention by treatment with bosentan, an oral endothelin receptor antagonist, Arthritis Rheum, vol.50, issue.12, pp.3985-3993, 2004.

M. Matucci-cerinic, C. P. Denton, D. E. Furst, M. D. Mayes, V. M. Hsu et al., Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial, Annals of the Rheumatic Diseases, vol.70, issue.1, pp.32-40, 2011.
DOI : 10.1136/ard.2010.130658

S. Abraham and V. Steen, Optimal management of digital ulcers in systemic sclerosis, Ther. Clin. Risk Manag, vol.11, pp.939-947, 2015.

R. Riemekasten, V. Silver, . Smith, I. Sulli, A. Tarner et al., Update of EULAR recommendations for the treatment of systemic sclerosis, Ann. Rheum. Dis, vol.76, issue.8, pp.1327-1339, 2017.

M. Matucci-cerinic, T. Krieg, L. Guillevin, B. Schwierin, D. Rosenberg et al., Elucidating the burden of recurrent and chronic digital ulcers in systemic sclerosis: long-term results from the DUO Registry, Annals of the Rheumatic Diseases, vol.31, issue.(Suppl 76), pp.1770-1776, 2016.
DOI : 10.1016/j.jbspin.2009.05.015

I. Mathian, U. Lazareth, J. Michon-pasturel, E. Viallard, C. Wierzbicka-hainaut et al., Ischemic Digital Ulcers Affect Hand Disability and Pain in Systemic Sclerosis, J. Rheumatol, vol.41, issue.7, pp.1317-1323, 2014.

E. Hachulla, P. Clerson, D. Launay, M. Lambert, S. Morell-dubois et al., Natural history of ischemic digital ulcers in systemic sclerosis: single-center retrospective longitudinal study, J. Rheumatol, vol.34, issue.12, pp.2423-2453, 2007.

F. Rannou, S. Poiraudeau, A. Berezné, T. Baubet, V. Le-guern et al., Assessing disability and quality of life in systemic sclerosis: Construct validities of the Cochin Hand Function Scale, Health Assessment Questionnaire (HAQ), Systemic Sclerosis HAQ, and Medical Outcomes Study 36-Item Short Form Health Survey, Arthritis & Rheumatism, vol.103, issue.1, pp.94-102, 2007.
DOI : 10.7326/0003-4819-118-8-199304150-00009

N. Peres, S. Morell-dubois, E. Hachulla, P. Y. Hatron, A. Duhamel et al., [Systemic sclerosis and occupational difficulties: Results of a prospective study], La Rev. Med. interne, 2017.

H. Zachariae, L. Halkier-sørensen, P. Bjerring, and L. Heickendorff, Treatment of ischaemic digital ulcers and prevention of gangrene with intravenous iloprost in systemic sclerosis, Acta Derm. Venereol, vol.76, issue.3, pp.236-244, 1996.

A. Kawald, G. R. Burmester, D. Huscher, C. Sunderkötter, and G. Riemekasten, Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud's phenomenon and systemic sclerosis: a randomized, open, single-center study, J. Rheumatol, vol.35, issue.9, pp.1830-1837, 2008.

M. Vandecandelaere, Administration d'ilomédine au sein d'une cohorte de 30 patients atteints d'ischémie digitale : évaluation des pratiques professionnelles et détermination de critères de bonne tolérance clinique, 2009.

Y. Benhamou, M. Vandecandelaere, R. Varin, M. L. Besnerais, N. Cailleux et al., Administration d???iloprost au sein d???une cohorte de 30??patients atteints d???isch??mie digitale??: d??termination de crit??res de bonne tol??rance clinique, La Revue de M??decine Interne, vol.31, issue.S1, p.78, 2010.
DOI : 10.1016/j.revmed.2010.03.443

M. Vayssairat, Preventive effect of an oral prostacyclin analog, beraprost sodium, on digital necrosis in systemic sclerosis. French Microcirculation Society Multicenter Group for the Study of Vascular Acrosyndromes, J. Rheumatol, vol.26, issue.10, pp.2173-2181, 1999.

E. Hachulla, P. Hatron, P. Carpentier, C. Agard, E. Chatelus et al., Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study, Annals of the Rheumatic Diseases, vol.353, issue.6, pp.1009-1015, 2016.
DOI : 10.1056/NEJMoa050010

URL : https://hal.archives-ouvertes.fr/hal-01466199

P. A. Merkel, K. Herlyn, R. W. Martin, J. J. Anderson, M. D. Mayes et al., Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon, Arthritis & Rheumatism, vol.42, issue.9, pp.2410-2420, 2002.
DOI : 10.1002/1529-0131(199911)42:11<2372::AID-ANR16>3.0.CO;2-J

C. G. Cote, C. Casanova, J. M. Marin, M. V. Lopez, V. Pinto-plata et al., Validation and comparison of reference equations for the 6-min walk distance test, European Respiratory Journal, vol.31, issue.3, pp.571-578, 2008.
DOI : 10.1183/09031936.00104507